Maris Laan1, Marina Grigorova, Ilpo T Huhtaniemi. 1. Human Molecular Genetics Research Group, Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia. maris.laan@ut.ee
Abstract
PURPOSE OF REVIEW: To review the current knowledge of genetic variants in the two genes affecting the individual responsiveness to follicle-stimulating hormone (FSH) action-the FSH beta-subunit (FSHB) and the FSH receptor (FSHR), as well as the pharmacogenetic ramifications of the findings. RECENT FINDINGS: Four common variants in the FSHB and the FSHR genes were shown to exhibit significant effect on FSH action: linked FSHR variants Thr307Ala and Asn680Ser determining common receptor isoforms, and gene expression affecting polymorphisms FSHR -29G/A and FSHB -211G/T. In women, the FSHR Thr307Ala/Asn680Ser polymorphisms show consistent predictive value for estimating the most optimal recombinant FSH dosage in controlled ovarian hyperstimulation (COH). The same variants exhibit a potential for the pharmacogenetic assessment of the treatment of polycystic ovarian syndrome. The FSHR -29G/A variant was also shown to contribute to ovarian response to COH. Pilot studies have suggested the FSHB -211 TT homozygous oligozoospermic men with genetically determined low concentration of FSH, as potentially the best responders to FSH treatment; furthermore, modulation of this response by FSHR polymorphisms is possible. SUMMARY: Genetic variants in FSHB and FSHR exhibit a potential for pharmacogenetic applications in selecting appropriate treatment options (timing and dosage) in male and female conditions requiring or benefiting from FSH therapy.
PURPOSE OF REVIEW: To review the current knowledge of genetic variants in the two genes affecting the individual responsiveness to follicle-stimulating hormone (FSH) action-the FSH beta-subunit (FSHB) and the FSH receptor (FSHR), as well as the pharmacogenetic ramifications of the findings. RECENT FINDINGS: Four common variants in the FSHB and the FSHR genes were shown to exhibit significant effect on FSH action: linked FSHR variants Thr307Ala and Asn680Ser determining common receptor isoforms, and gene expression affecting polymorphisms FSHR-29G/A and FSHB-211G/T. In women, the FSHRThr307Ala/Asn680Ser polymorphisms show consistent predictive value for estimating the most optimal recombinant FSH dosage in controlled ovarian hyperstimulation (COH). The same variants exhibit a potential for the pharmacogenetic assessment of the treatment of polycystic ovarian syndrome. The FSHR-29G/A variant was also shown to contribute to ovarian response to COH. Pilot studies have suggested the FSHB -211 TT homozygous oligozoospermic men with genetically determined low concentration of FSH, as potentially the best responders to FSH treatment; furthermore, modulation of this response by FSHR polymorphisms is possible. SUMMARY: Genetic variants in FSHB and FSHR exhibit a potential for pharmacogenetic applications in selecting appropriate treatment options (timing and dosage) in male and female conditions requiring or benefiting from FSH therapy.
Authors: Li Sun; Yuanzhen Peng; Allison C Sharrow; Jameel Iqbal; Zhiyuan Zhang; Dionysios J Papachristou; Samir Zaidi; Ling-Ling Zhu; Beatrice B Yaroslavskiy; Hang Zhou; Alberta Zallone; M Ram Sairam; T Rajendra Kumar; Wei Bo; Jonathan Braun; Luis Cardoso-Landa; Mitchell B Schaffler; Baljit S Moonga; Harry C Blair; Mone Zaidi Journal: Cell Date: 2006-04-21 Impact factor: 41.582
Authors: Hellevi Peltoketo; Leena Strauss; Riikka Karjalainen; Meilin Zhang; Gordon W Stamp; Deborah L Segaloff; Matti Poutanen; Ilpo T Huhtaniemi Journal: Endocrinology Date: 2010-02-19 Impact factor: 4.736
Authors: Janneke A Burgers; Sharon Lie Fong; Yvonne V Louwers; Olivier Valkenburg; Frank H de Jong; Bart C J M Fauser; Joop S E Laven Journal: J Clin Endocrinol Metab Date: 2010-09-15 Impact factor: 5.958
Authors: A Overbeek; E A M Kuijper; M L Hendriks; M A Blankenstein; I J G Ketel; J W R Twisk; P G A Hompes; R Homburg; C B Lambalk Journal: Hum Reprod Date: 2009-04-28 Impact factor: 6.918
Authors: Marina Grigorova; Margus Punab; Olev Poolamets; Piret Kelgo; Kristo Ausmees; Paul Korrovits; Vladimir Vihljajev; Maris Laan Journal: J Clin Endocrinol Metab Date: 2009-11-06 Impact factor: 5.958
Authors: Tarek M K Motawi; Sherine M Rizk; Nadine W Maurice; Ahmed Mohamed Maged; Ayman N Raslan; Ahmed H Sawaf Journal: J Assist Reprod Genet Date: 2017-08-19 Impact factor: 3.412
Authors: M Grigorova; M Punab; O Poolamets; S Sõber; V Vihljajev; B Žilaitienė; J Erenpreiss; V Matulevičius; I Tsarev; M Laan Journal: Andrology Date: 2012-11-29 Impact factor: 3.842
Authors: Marina Grigorova; Margus Punab; Anna Maria Punab; Olev Poolamets; Vladimir Vihljajev; Birutė Zilaitienė; Juris Erenpreiss; Valentinas Matulevičius; Maris Laan Journal: PLoS One Date: 2014-04-09 Impact factor: 3.240
Authors: Belén Monge-Ochoa; Luis Montoro; Elisa Gil-Arribas; Julio Montoya; Eduardo Ruiz-Pesini; Manuel J López-Pérez; Francisco de Castro; Carmen Díez-Sánchez Journal: J Assist Reprod Genet Date: 2021-08-03 Impact factor: 3.357